- Home
- FMS vs MRNA Comparison
FMS vs MRNA Comparison
Compare FMS & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMS
- MRNA
- Stock Information
- Founded
- FMS 1996
- MRNA 2010
- Country
- FMS Germany
- MRNA United States
- Employees
- FMS N/A
- MRNA 5800
- Industry
- FMS Misc Health and Biotechnology Services
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FMS Health Care
- MRNA Health Care
- Exchange
- FMS Nasdaq
- MRNA Nasdaq
- Market Cap
- FMS 15.9B
- MRNA 11.1B
- IPO Year
- FMS 1996
- MRNA 2018
- Fundamental
- Price
- FMS $27.52
- MRNA $32.71
- Analyst Decision
- FMS Hold
- MRNA Hold
- Analyst Count
- FMS 1
- MRNA 19
- Target Price
- FMS $30.00
- MRNA $48.13
- AVG Volume (30 Days)
- FMS 371.1K
- MRNA 9.7M
- Earning Date
- FMS 07-29-2025
- MRNA 07-31-2025
- Dividend Yield
- FMS 2.07%
- MRNA N/A
- EPS Growth
- FMS 27.83
- MRNA N/A
- EPS
- FMS 2.28
- MRNA N/A
- Revenue
- FMS $21,068,786,202.00
- MRNA $3,177,000,000.00
- Revenue This Year
- FMS $2.74
- MRNA N/A
- Revenue Next Year
- FMS $3.60
- MRNA $9.70
- P/E Ratio
- FMS $24.26
- MRNA N/A
- Revenue Growth
- FMS 0.10
- MRNA N/A
- 52 Week Low
- FMS $17.93
- MRNA $23.15
- 52 Week High
- FMS $30.46
- MRNA $129.39
- Technical
- Relative Strength Index (RSI)
- FMS 44.61
- MRNA 72.45
- Support Level
- FMS $27.44
- MRNA $29.72
- Resistance Level
- FMS $28.87
- MRNA $33.65
- Average True Range (ATR)
- FMS 0.34
- MRNA 1.38
- MACD
- FMS -0.07
- MRNA 0.62
- Stochastic Oscillator
- FMS 50.37
- MRNA 89.06
About FMS Fresenius Medical Care AG
Fresenius Medical Care is the largest dialysis company in the world, treating about 300,000 patients from nearly 3,700 clinics worldwide as of December 2024. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.